Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lepu Biopharma Co., Ltd. has announced that its drug candidate MRG003, aimed at treating recurrent or metastatic nasopharyngeal cancer, has been accepted for review and granted priority by China’s NMPA. This marks a significant milestone for the company, potentially accelerating MRG003’s commercialization and bolstering the company’s competitiveness in the oncology market. However, the company warns that there is no certainty of MRG003’s successful development or market success.
For further insights into HK:2157 stock, check out TipRanks’ Stock Analysis page.